IL278633B2 - Immunoconjugates - Google Patents

Immunoconjugates

Info

Publication number
IL278633B2
IL278633B2 IL278633A IL27863320A IL278633B2 IL 278633 B2 IL278633 B2 IL 278633B2 IL 278633 A IL278633 A IL 278633A IL 27863320 A IL27863320 A IL 27863320A IL 278633 B2 IL278633 B2 IL 278633B2
Authority
IL
Israel
Prior art keywords
immunoconjugate
linker
attachment
point
residue
Prior art date
Application number
IL278633A
Other languages
English (en)
Hebrew (he)
Other versions
IL278633A (en
IL278633B1 (en
Original Assignee
Bolt Biotherapeutics Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66691077&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL278633(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bolt Biotherapeutics Inc, Univ Leland Stanford Junior filed Critical Bolt Biotherapeutics Inc
Publication of IL278633A publication Critical patent/IL278633A/en
Publication of IL278633B1 publication Critical patent/IL278633B1/en
Publication of IL278633B2 publication Critical patent/IL278633B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL278633A 2018-05-17 2019-05-17 Immunoconjugates IL278633B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673015P 2018-05-17 2018-05-17
US201862724259P 2018-08-29 2018-08-29
PCT/US2019/032947 WO2019222676A1 (en) 2018-05-17 2019-05-17 Immunoconjugates

Publications (3)

Publication Number Publication Date
IL278633A IL278633A (en) 2021-01-31
IL278633B1 IL278633B1 (en) 2024-12-01
IL278633B2 true IL278633B2 (en) 2025-04-01

Family

ID=66691077

Family Applications (1)

Application Number Title Priority Date Filing Date
IL278633A IL278633B2 (en) 2018-05-17 2019-05-17 Immunoconjugates

Country Status (10)

Country Link
US (1) US20210154316A1 (enExample)
EP (1) EP3793613B1 (enExample)
JP (2) JP2021524447A (enExample)
KR (1) KR20210013096A (enExample)
CN (1) CN112153988A (enExample)
AU (1) AU2019270178A1 (enExample)
CA (1) CA3100544A1 (enExample)
ES (1) ES3003787T3 (enExample)
IL (1) IL278633B2 (enExample)
WO (1) WO2019222676A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
CA3110510A1 (en) * 2018-08-29 2020-03-05 Bolt Biotherapeutics, Inc. Immunoconjugates targeting egfr
AU2019337654A1 (en) * 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
US20220152215A1 (en) * 2019-03-15 2022-05-19 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting CEA
WO2020190731A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220226491A1 (en) * 2019-03-15 2022-07-21 Bolt Biotherapeutics, Inc. Immunoconjugates Targeting PD-L1
WO2020190725A1 (en) * 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220143012A1 (en) * 2019-03-15 2022-05-12 Bolt Biotherapeutics, Inc. Macromolecule-Supported TLR Agonists
EP4048314A1 (en) * 2019-10-25 2022-08-31 Bolt Biotherapeutics, Inc. Macromolecule-supported thienoazepine compounds, and uses thereof
TWI857167B (zh) 2019-10-25 2024-10-01 美商博特生物治療公司 噻吩并氮呯免疫結合物及其用途
CA3169117A1 (en) * 2020-02-25 2021-09-02 Bolt Biotherapeutics, Inc. Cancer treatment methods
US20230293716A1 (en) * 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CN113999313A (zh) * 2020-07-28 2022-02-01 百奥泰生物制药股份有限公司 抗her2抗体及其应用
IL300316A (en) * 2020-08-13 2023-04-01 Bolt Biotherapeutics Inc Immune conjugates of pyrazolozapines and their uses
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
BR112023015561A2 (pt) * 2021-02-03 2023-11-14 Univ Minnesota Compostos imunoestimuiladores e conjugados
KR102917231B1 (ko) * 2021-03-08 2026-01-26 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항체 면역 작용제 접합체 및 이의 적용
EP4331616A4 (en) * 2021-05-13 2026-03-18 Univ Tsinghua ANTIBODY-DRUG CONJUGATE, RELATED PREPARATION PROCESS AND ASSOCIATED USE
WO2023044016A2 (en) * 2021-09-17 2023-03-23 Cspc Dophen Corporation Antibody immune-stimulant conjugates and use thereof
JP2024539993A (ja) 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用
AU2023253036A1 (en) * 2022-04-15 2024-10-17 Mabsoft Therapeutics Conjugate comprising toll-like receptor agonist
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100634A2 (en) * 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2018009916A1 (en) * 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
US20040101909A1 (en) 2002-08-20 2004-05-27 Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 Purification of polyreactive autoantibodies and uses thereof
US20070259907A1 (en) 2004-06-18 2007-11-08 Prince Ryan B Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US8354249B2 (en) 2005-08-11 2013-01-15 Omrix Biopharmaceuticals Ltd. Intravenous immunoglobulin composition
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
US20130108619A1 (en) 2011-11-02 2013-05-02 Isaac Melamed Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
PT3265458T (pt) 2015-03-06 2019-02-13 Hoffmann La Roche Compostos de dicarboxamida de benzazepina
US20170158772A1 (en) 2015-12-07 2017-06-08 Opi Vi - Ip Holdco Llc Compositions of antibody construct - agonist conjugates and methods of use thereof
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
SG10202110182PA (en) 2017-03-15 2021-10-28 Silverback Therapeutics Inc Benzazepine compounds, conjugates, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100634A2 (en) * 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
WO2018009916A1 (en) * 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates

Also Published As

Publication number Publication date
JP2024059814A (ja) 2024-05-01
IL278633A (en) 2021-01-31
EP3793613A1 (en) 2021-03-24
EP3793613C0 (en) 2025-01-01
KR20210013096A (ko) 2021-02-03
WO2019222676A1 (en) 2019-11-21
CA3100544A1 (en) 2019-11-21
US20210154316A1 (en) 2021-05-27
IL278633B1 (en) 2024-12-01
CN112153988A (zh) 2020-12-29
JP2021524447A (ja) 2021-09-13
AU2019270178A1 (en) 2021-01-07
ES3003787T3 (en) 2025-03-11
EP3793613B1 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
IL278633B1 (en) Immunoconjugates
JP2021524447A5 (enExample)
JP7002467B2 (ja) 新規のｂ７‐ｈ３結合分子、その抗体薬物コンジュゲート、及びその使用方法
CN110914306B (zh) 检查点抑制物双特异性抗体
US9777071B2 (en) Anti-DPEP3 antibodies and methods of use
IL285287B2 (en) Antibodies to tigit
US10428156B2 (en) Anti-MFI2 antibodies and methods of use
JP2019520352A5 (enExample)
US20220340673A1 (en) Antibody targeting bcma, bispecific antibody, and use thereof
US20220002432A1 (en) Cd38 and icam1 antibodies and uses thereof
KR20180088445A (ko) 신규한 항-클라우딘 항체 및 사용 방법
JP2017535246A5 (enExample)
KR20160070191A (ko) 신규한 항-클라우딘 항체 및 사용 방법
RU2014148162A (ru) Анти-pmel17 антитела и их иммуноконъюгаты
JP2020506703A5 (enExample)
JP2014522850A5 (enExample)
JP2017534253A5 (enExample)
RU2012139197A (ru) Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
JP2022533538A5 (enExample)
JP2013519375A5 (enExample)
US20210261670A1 (en) Novel anti-bmpr1b antibodies and methods of use
RU2014140116A (ru) Антитела против pdgf-c
WO2015095766A2 (en) Novel anti-lingo1 antibodies and methods of use
JP2015529656A5 (enExample)
Riester et al. Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma